IQVIA Holdings Inc. ($IQV) Stock Forecast: Up 5.4% Today

What is IQVIA Holdings Inc.?

IQVIA Holdings (IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the healthcare industry. The company focuses on utilizing data and AI-driven insights to improve healthcare outcomes and drive innovation in the sector.

Why is IQVIA Holdings Inc. going up?

IQV stock is up 5.4% on Feb 6, 2026 20:28

• Despite adjustments in price targets by various analysts, IQVIA Holdings (IQV) witnessed significant bullish movement in the market today.
• The market is responding positively to IQVIA's robust performance in Q4 2025, surpassing revenue projections and demonstrating a commitment to AI-driven solutions for future expansion.
• Analysts' concerns regarding margin pressures and sustainability of growth have been somewhat overshadowed by the company's strategic acquisitions, streamlined business operations, and optimistic 2026 forecast.
• Investors appear to find IQVIA Holdings' current valuation appealing for potential growth opportunities, despite short-term challenges highlighted by analysts.

IQV Price Chart

IQV Technical Analysis

IQV News

IQV Analyst Rating Update: Stifel Lowers Price Target to $220 | IQV Stock News

Stifel analyst Shlomo Rosenbaum has maintained a "Buy" rating for IQVIA Holdings (IQV) but lowered the price target from $273.00 to $220.00, a 19.41% decrease. This adjustment reflects potential changes in the company's valuation, despite other analysts recently raising their price targets for IQVIA. The average target price from 21 analysts is $252.36, indicating an upside of 35.25% from the current price, with a consensus "Outperform" recommendation.

https://www.gurufocus.com/news/8591537/iqv-analyst-rating-update-stifel-lowers-price-target-to-220-iqv-stock-news

Leerink Partners Adjusts Price Target on IQVIA Holdings to $228 From $256, Maintains Outperform Rating

Leerink Partners has lowered its price target for IQVIA Holdings (IQV) to $228 from $256, while reaffirming an "Outperform" rating on the stock. This adjustment comes amidst a flurry of similar price target revisions from other financial institutions, including UBS, Evercore ISI, BMO Capital, Barclays, JPMorgan, Citigroup, Jefferies, and Stifel, all occurring on the same day. The changes follow IQVIA's recent Q4 2025 earnings report and their 2026 guidance, which included weaker-than-expected EPS forecasts.

https://www.marketscreener.com/news/leerink-partners-adjusts-price-target-on-iqvia-holdings-to-228-from-256-maintains-outperform-rati-ce7e5ad9dd8ef121

IQV Q4 Deep Dive: Market Cautions Despite Revenue Beat and AI Strategy Emphasis

IQVIA (IQV) reported strong Q4 CY2025 results, beating revenue expectations with sales up 10.3% year-on-year, and emphasizing its AI strategy while facing market cautions. Despite exceeding top-line growth and adjusted EPS estimates, the stock reacted negatively due to margin compression and concerns about the sustainability of gains. The company plans to focus on AI-driven solutions, strategic acquisitions, and a simplified business structure to drive future growth, though higher interest expenses and operational costs are expected to impact near-term profitability.

https://finviz.com/news/302457/iqv-q4-deep-dive-market-cautions-despite-revenue-beat-and-ai-strategy-emphasis

IQVIA Holdings Inc. (NYSE:IQV) Q4 2025 Earnings Call Transcript

IQVIA Holdings Inc. (NYSE: IQV) reported strong Q4 and full-year 2025 results, with Q4 revenue exceeding guidance and net bookings growing 7% year-over-year. The company addressed concerns about AI disruption, emphasizing its proprietary data assets, deep domain expertise, and integrated solutions as key competitive advantages, positioning AI as an opportunity for productivity and enhanced services rather than a threat. IQVIA also announced a simplified organizational structure into two reporting segments, Commercial Solutions and R&D Solutions, and provided financial guidance for 2026, including expected revenue between $17.159 billion and $17.359 billion.

https://www.insidermonkey.com/blog/iqvia-holdings-inc-nyseiqv-q4-2025-earnings-call-transcript-1690275/

Jefferies lowers IQVIA stock price target to $255 on margin pressures

Jefferies has lowered its price target for IQVIA Holdings (NYSE:IQV) to $255.00 from $270.00, while maintaining a Buy rating, citing ongoing margin pressures despite strong revenue growth in Q4 2025. The company's stock has dropped significantly and is considered oversold, yet Jefferies sees a positive risk/reward given its near all-time low valuation, partly due to AI concerns. IQVIA's Q4 results exceeded expectations with $16.31 billion in revenue and a 1.18x book-to-bill ratio, but forecasted flat EBITDA margins and increased interest expenses for FY26 contributed to the revised outlook.

https://www.investing.com/news/analyst-ratings/jefferies-lowers-iqvia-stock-price-target-to-255-on-margin-pressures-93CH-4490117

Trending Today

BlackLine, Inc. ($BL) Stock Forecast: Up 5.1% Today

Crowdstrike Holdings Inc. ($CRWD) Stock Forecast: Up 5.0% Today

Chewy Inc ($CHWY) Stock Forecast: Up 5.1% Today

International Paper Company ($IP) Stock Forecast: Up 5.8% Today

Coupang LLC ($CPNG) Stock Forecast: Up 5.1% Today

Oracle Corporation ($ORCL) Stock Forecast: Up 5.1% Today

Aurora Cannabis Inc. ($ACB) Stock Forecast: Up 5.0% Today

Corebridge Financial ($CRBG) Stock Forecast: Up 5.2% Today

Intel Corporation ($INTC) Stock Forecast: Up 5.2% Today

Palantir Technologies Inc ($PLTR) Stock Forecast: Up 5.3% Today

IQVIA Holdings Inc. Price History

28.09.2025 - IQV Stock was up 0.8%

• IQVIA Holdings (IQV) reported better-than-expected earnings and revenue for the third quarter, indicating strong financial performance.
• The company's focus on biopharma strength and cost control has likely contributed to the positive results, showcasing its ability to adapt to industry dynamics.
• Investors may be optimistic about IQV's future prospects, considering its ability to outperform expectations in a challenging market environment.
• The bullish movement in IQV's stock price could be a reflection of confidence in the company's strategic direction and growth potential.

24.06.2025 - IQV Stock was up 7.6%

• IQV stock had a strong bullish movement today.
• The positive earnings report for the second quarter, with earnings and revenue beating estimates and showing year-over-year growth, likely fueled the bullish trend.
• Despite the strong performance, the cut in 2025 EBITDA guidance may have tempered some of the initial excitement in the market.
• The overall market uncertainty could have been overshadowed by IQV's impressive financial results, leading to the bullish movement in the stock.

05.01.2026 - IQV Stock was down 6.6%

• Despite exceeding earnings forecasts and providing optimistic guidance for 2026, IQV's stock experienced a significant drop of 9.02% in pre-market trading.
• The market's reaction to IQV's strong financial performance could be attributed to broader market dynamics and concerns about the disruptive potential of AI technologies.
• While IQV showcased robust profitability and growth, the high debt-to-equity ratio and potential liquidity challenges highlighted in the analysis might have contributed to the bearish movement in the stock.
• CEO Ari Bousbib's emphasis on AI as a positive enabler for IQVIA's business, along with strategic acquisitions and AI advancements, could be key factors to monitor for potential market recovery.

05.01.2026 - IQV Stock was down 7.6%

• Despite strong financial performance in the fourth quarter, surpassing revenue projections, IQV encountered a downward trend in the market.
• The market decline may stem from concerns surrounding the company's high debt-to-equity ratio and potential liquidity issues, possibly overshadowing the positive financial results.
• Moreover, comparisons depicting IQV as a more attractive investment choice than Idexx Laboratories could have impacted investor confidence, leading to profit-taking or a shift in investment strategies.
• Investors appear wary leading up to the upcoming earnings release, seeking clarity on margin growth and new enterprise partnerships, particularly within the Technology & Analytics Solutions sector, amid budget constraints in the biotech industry.

05.00.2026 - IQV Stock was up 1.0%

• The increased stake by North Growth Management Ltd. and positive Q3 earnings results exceeding expectations likely contributed to the bullish movement.
• Despite the reduction in holdings by JARISLOWSKY FRASER Ltd and Generali Asset Management SPA SGR, the overall sentiment from analysts and brokers with raised price targets and ratings supported the stock's upward trajectory.
• The contrast between IQVIA's steady growth and undervalued perception of ICON plc in the clinical research space may have also attracted investors looking for reliable long-term investments.
• Overall, the combination of positive institutional investments, strong financial performance, and optimistic future guidance propelled IQV's bullish movement in the market today.

20.00.2026 - IQV Stock was up 1.8%

• IQV's bullish movement can be attributed to its strong financial performance, technical indicators, and analyst confidence, indicating a promising investment opportunity.
• The increased stake by an investment firm and the company's strong Q3 earnings, beating analyst expectations, likely contributed to the positive market movement.
• Additionally, the overall rebound in the healthcare sector, driven by increased clarity on drug pricing and tariffs, may have further boosted IQV's performance as a top pick for investors in 2026.
• The company's current trading above key moving averages and consensus "Moderate Buy" rating with an average target price near $249.19 reinforce the bullish outlook for IQV.

06.00.2026 - IQV Stock was up 5.5%

• Some investors, including Community Trust & Investment Co., have reduced their stakes in IQVIA Holdings Inc., while others like Asset Dedication LLC and J.Safra Asset Management Corp. have increased their holdings, showing mixed sentiments among investors.
• IQVIA stock reached a 52-week high due to strong market performance, recent strategic decisions such as refinancing loans and a collaboration with Amazon Web Services, and positive adjustments in analyst price targets, reflecting investor confidence and growth prospects.
• The temporary suspension of the new 340B Drug Pricing Program rebate model may have had a positive impact on IQVIA by easing financial pressures on hospitals and potentially increasing demand for IQVIA's services in the life sciences sector.
• Despite competition from companies like Charles River Laboratories and ICON plc, IQVIA's strategic positioning and recent positive developments are likely contributing to its bullish market movement today.

04.01.2026 - IQV Stock was down 13.6%

• IQV's stock price fell by 9.18% on February 3rd, closing at $210.00.
• Investor caution and profit-taking prior to the upcoming Q4 earnings report on February 5th likely contributed to this decline.
• Despite the recent drop, analysts are optimistic about IQV's future, suggesting potential for significant growth and indicating that short-term fluctuations may be causing an overreaction in the market.
• IQV's stock underperformance relative to industry competitors and broader market indices hints at broader market sentiment and sector-specific influences impacting the bearish movement.

03.01.2026 - IQV Stock was down 9.4%

• IQV experienced a bearish movement likely due to:
• Analysts' cautious outlook on the company's Q4 earnings despite a history of positive surprises.
• Institutional investors adjusting their positions, with Running Oak Capital LLC selling shares and others increasing stakes, possibly signaling mixed sentiments in the market.
• The broader market reaction to another company's decline post-earnings beat, indicating sector-wide concerns over future guidance and valuation.
• The AI-generated analysis pointing to weak near and mid-term sentiment, contributing to the negative market movement for IQV.

03.01.2026 - IQV Stock was down 2.6%

• Running Oak Capital LLC reduced its stake in IQVIA during Q3, which might have signaled a lack of confidence in the company's future prospects, contributing to the bearish movement.
• Despite positive earnings reported by Thermo Fisher Scientific, concerns over academic and government spending, leadership changes, and elevated valuation in the sector led to a broader decline, potentially impacting IQVIA's stock negatively.
• The increase in institutional ownership, as seen with Nichols & Pratt Advisers LLP MA and Mediolanum International Funds Ltd, could indicate a positive sentiment towards IQVIA, but the overall market sentiment might have overshadowed these individual moves, resulting in the bearish trend.
• The bullish market movement in the Pharmacoeconomics industry, with major players like IQVIA being highlighted, could suggest long-term growth potential for the sector, despite the short-term bearish movement in IQV's stock.

06.01.2026 - IQV Stock was up 5.4%

• Despite adjustments in price targets by various analysts, IQVIA Holdings (IQV) witnessed significant bullish movement in the market today.
• The market is responding positively to IQVIA's robust performance in Q4 2025, surpassing revenue projections and demonstrating a commitment to AI-driven solutions for future expansion.
• Analysts' concerns regarding margin pressures and sustainability of growth have been somewhat overshadowed by the company's strategic acquisitions, streamlined business operations, and optimistic 2026 forecast.
• Investors appear to find IQVIA Holdings' current valuation appealing for potential growth opportunities, despite short-term challenges highlighted by analysts.

04.11.2025 - IQV Stock was down 5.2%

• Today, the market witnessed a bearish movement despite IQV's recent stock price increase and optimistic Q3 financial results.
• The decline could be attributed to some investors seizing the opportunity to take profits after the stock's substantial growth in recent months.
• Analysts' positive outlook on IQVIA Holdings, evident through the "Strong Buy" consensus rating and raised price targets, implies that the current bearish trend may be a temporary correction rather than a prolonged shift.
• Amidst uncertainties in the broader market, investors appear to be reassessing their positions in IQVIA Holdings, resulting in a bearish movement despite favorable company-specific developments.